PagrindinisCVAC • NASDAQ
add
CureVac BV
Ankstesnė uždarymo kaina
5,12 $
Dienos intervalas
5,10 $ - 5,16 $
Metų intervalas
2,48 $ - 5,72 $
Bendroji vertė rinkoje
1,15 mlrd. USD
Vidutinė prekybos apimtis
1,31 mln.
Kainos ir pajamų santykis
7,70
Pajamos iš dividendų
-
Pagrindinė akcijų birža
NASDAQ
Aktualios naujienos
AD HOC NEWS
prieš 17 valandų
CureVac’s Path as an Independent Company Concludes with BioNTech Takeover
0,26 %
Finansiniai rodikliai
Pajamų ataskaita
Pajamos
Grynosios pajamos
| (EUR) | 2025-09info | Metinis pokytis |
|---|---|---|
Pajamos | 54,13 mln. | −89,04 % |
Veiklos sąnaudos | −256,45 mln. | −347,56 % |
Grynosios pajamos | 273,23 mln. | −19,17 % |
Grynojo pelno marža | 504,73 | 637,48 % |
Pelnas tenkantis vienai akcijai | 1,21 | −19,33 % |
EBITDA | 314,57 mln. | −15,64 % |
Taikomas mokesčio tarifas | 11,17 % | — |
Balansas
Visas turtas
Visi įsipareigojimai
| (EUR) | 2025-09info | Metinis pokytis |
|---|---|---|
Lėšos, trump. investicijos | 416,09 mln. | — |
Visas turtas | 1,14 mlrd. | — |
Visi įsipareigojimai | 267,39 mln. | — |
Visos paprastosios akcijos | 871,23 mln. | — |
Išleistos akcijos | 180,95 mln. | — |
Kaina / apskaitinė vertė | 1,06 | — |
Turto grąža | 84,87 % | — |
Kapitalo grąža | 101,46 % | — |
Pinigų srautas
Grynasis pokytis (grynaisiais pinigais)
| (EUR) | 2025-09info | Metinis pokytis |
|---|---|---|
Grynosios pajamos | 273,23 mln. | −19,17 % |
Pinigai iš operacijų | 29,86 mln. | −91,57 % |
Pinigai iš investicijų | −322,00 tūkst. | 90,24 % |
Pinigai iš finansavimo | −1,29 mln. | 13,78 % |
Grynasis pokytis (grynaisiais pinigais) | 23,39 mln. | −93,29 % |
Laisvas pinigų srautas | −67,46 mln. | — |
Apie
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, a disease caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Generalinis direktorius
Įkurta
2000
Svetainė
Darbuotojų skaičius
904
